ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 22 filers reported holding ASCENDIS PHARMA A/S in Q3 2016. The put-call ratio across all filers is - and the average weighting 1.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $67,424,000 | -99.9% | 700,000 | +40.0% | 6.19% | -3.1% |
| Q2 2019 | $57,575,000,000 | +79438.9% | 500,000 | -18.7% | 6.39% | -10.8% |
| Q1 2019 | $72,386,000 | +7031.6% | 615,000 | +703.8% | 7.16% | +2362.2% |
| Q2 2016 | $1,015,000 | -81.6% | 76,511 | -75.4% | 0.29% | -86.4% |
| Q2 2015 | $5,502,000 | -6.7% | 311,222 | -8.4% | 2.14% | -17.3% |
| Q1 2015 | $5,896,000 | – | 339,863 | – | 2.60% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |